Materias dentro de su búsqueda.
Mostrando 3,121 - 3,140 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.30s Limitar resultados
  1. 3121
    “…More importantly, the quantification of HER2 MS images has higher prediction accuracy than that of HER2 RGB images (69.6% vs 65.0%) on 5-DFS. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Comparative Performance Analysis of Multispectral and RGB Imaging on HER2 Status Evaluation for the Prediction of Breast Cancer Prognosis()
  2. 3122
    “…An additional electrode (Ad(HER)) connected to the anode of the first SC-MFC and placed in the fourth SC-MFC evolved hydrogen. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Co-generation of hydrogen and power/current pulses from supercapacitive MFCs using novel HER iron-based catalysts
  3. 3123
    por Doss, Bhawanee
    Publicado 1873
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Tetanus Resulting from Retained Placenta until Putrid, in a Young Woman Miscarried in Her Third Month: Recovery
  4. 3124
    por Bucknill, John Charles
    Publicado 1854
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Bill Intituled 'An Act to Amend an Act Passed in the Ninth Year of Her Majesty, for the Regulation of the Care and Treatment of Lunatics'
  5. 3125
    por Bucknill, John Charles
    Publicado 1853
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Bill Intituled 'An Act to Amend an Act Passed in the Ninth Year of Her Majesty, for the Regulation of the Care and Treatment of Lunatics
  6. 3126
    “…PURPOSE: Human epidermal growth factor receptor 3 (HER3) has been identified as an important component of many receptor tyrosine kinase-driven cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer
  7. 3127
    “…Amplification of the HER2 gene in these tumors results in a substantial increase in HER2 mRNA levels, and consequently, HER2 protein levels. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer
  8. 3128
    “…Human epidermal growth receptor 2 (Her2, Neu, ErbB2) is a driver oncogene in human cancers, particularly breast cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Her2 oncogene transformation enhances 5-aminolevulinic acid-mediated protoporphyrin IX production and photodynamic therapy response
  9. 3129
    “…The purpose of this study was to retrospectively review the pathologic complete response (pCR) rate from patients (n=86) with stage II and III HER2-positive breast cancer treated with neoadjuvant chemotherapy at our institution from 2008 to 2013 and to determine possible predictive and prognostic factors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
  10. 3130
    “…Overexpression of human epidermal growth factor receptor 3 (HER3) is involved in resistance to several therapies for malignant tumours. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct
  11. 3131
    “…MATERIALS/METHODS: Between Jan. 2010 to Feb. 2016, 48 HER2 negative MBC patients who failed anthracycline and taxane based chemotherapy were enrolled. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer
  12. 3132
    “…To assess the need for adjustment in the likelihood of germline BRCA1/2 mutations in women with HER2+ breast cancers. We analysed primary mutation screens on women with breast cancer with unequivocal HER2 overexpression and assessed the likelihood of BRCA1/BRCA2 mutations by age, oestrogen receptor status and Manchester score. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores
  13. 3133
    “…BACKGROUND: Approximately 15%–20% of all diagnosed breast cancers are characterized by amplified and overexpressed HER2 (= ErbB2). These breast cancers are aggressive and have a poor prognosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
  14. 3134
    “…OBJECTIVE: HER2 overexpression is associated with aggressive phenotypes in breast cancer, including increased tumor proliferation, greater invasiveness, and reduced overall survival. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer
  15. 3135
    “…MAPK rebound caused by BRAF/MEK inhibitors-induced activation of HER2/HER3 is a resistance mechanism, and combination with HER inhibitor to prevent MAPK rebound may sensitize BRAF(V600E)-mutant thyroid cancer cells to redifferentiation therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
  16. 3136
    “…BACKGROUND: The current exploratory analysis was performed to evaluate the efficacy and safety of everolimus for treatment of human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer in the Asian subset of patients in the BOLERO-1 trial. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1
  17. 3137
    por Altundag, Kadri
    Publicado 2017
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy'
  18. 3138
    “…Drug-refractory breast cancers include HER2+ tumors that have acquired resistance to HER2-targeted antibodies and kinase inhibitors, and “Triple-Negative” Breast Cancers (TNBCs) that lack the therapeutic targets Estrogen Receptor, Progesterone Receptor, and HER2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells
  19. 3139
    “…Based on HER2 heterogeneity, the patients were divided into a HER2(homogeneous) group and a HER2(heterogeneous) group. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type
  20. 3140
    “…Univariate analysis showed that positive lymph node status was significantly correlated with the increased risk of distant metastasis in all subtypes except the hormone receptor-negative, HER2-positive (HR−/HER2+) subtype. Most p-genes were significantly associated with poor prognosis in patients with the HR+/HER2− subtype, whereas i-genes correlated with a favorable outcome in patients with HR−/HER2+ breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
Herramientas de búsqueda: RSS